<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753662</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-08-AA-0397-CTIL</org_study_id>
    <nct_id>NCT00753662</nct_id>
  </id_info>
  <brief_title>Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease</brief_title>
  <acronym>TMS in AD</acronym>
  <official_title>Phase 2 (Feasibility) Study of Transcranial Magnetic Stimulation as Additional Therapy to Drug Treatment in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the ability of Transcranial Magnetic
      Stimulation with H2 coil to prefrontal and parieto-temporal cortex to improve cognitive
      performance in patients with Alzheimer's disease which received drug treatment. This study is
      a single-center, double-blind 4 months duration trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome measure: ADAS-COG (time frame baseline, 2 months, 4 months) Secondary outcome
      measure: CGI-C, Neuropsychological computerized test (Mindstream), FAB,ADL, Beck Depression
      Inventory-time frame baseline,1 month (visit 12) 2 months (visit 16), 4 months (visit 17).

      Estimated enrollment: 45 patients Estimated Study start Date: November 2008 Estimated Study
      Completion date: November 2012 Number of arms: 3 Interventions details: H2 coil device for
      Transcranial Magnetic Stimulation with MAGSTIM to prefrontal and parieto-temporal regions
      bilaterally with frequency 10Hz in one arm, 1Hz in the second arm, and sham-stimulation with
      frequency 10Hz/1Hz in third arm.

      Ages: 50-80 Genders: both
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-COG</measure>
    <time_frame>Baseline, 1 month (visit 12), 2 months (visit 16), 4 months (visit 17)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-C, Neuropsychological computerized test (Mindstream),CGI-C,FAB,ADL, Beck Depression Inventory.</measure>
    <time_frame>Baseline, 1 month (visit 12), 2 months (visit 16), 4 months (visit 17)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients in group 1 will be treated with 1Hz frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients in group 2 will be treated with 1Hz frequency 10Hz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>15 patients in group 3 will be treated with SHAM (1Hz/10Hz)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1Hz TMS with H2 coil</intervention_name>
    <description>1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex</intervention_name>
    <description>10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex</description>
    <arm_group_label>2</arm_group_label>
    <other_name>10Hz TMS with H2 coil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM TMS with H2 coil</intervention_name>
    <description>SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent will be obtained

          -  diagnostic evidence of probable AD consistent with DSM IV

          -  stable treatment with Acetylcholine-Esterase Inhibitors or/and Memantine for 5 weeks
             prior to screening

          -  stable dose treatment with other drugs

          -  MMSE &lt;25

        Exclusion Criteria:

          -  Patients with neurological or psychiatric disorders that affect cognition but are
             distinguishable from AD

          -  Patients who are unwilling or unable to fulfill the requirements of the study

          -  Severe personality disorder

          -  Malignant or untreated Hypertension

          -  History of Epilepsy

          -  History of Head trauma

          -  Metal implant in head, cardiac pacemaker, medical pump

          -  Drug or alcohol addiction

          -  Involvement in any other clinical trial during the preceding 3 month

          -  Patient who are unwilling or unable to give Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alissa Ash, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alissa Ash, Dr.</last_name>
    <phone>+972-3-6973698</phone>
    <email>elissaa@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center, Neurology Department</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Ash, Dr.</last_name>
      <phone>972-3-6973698</phone>
      <email>elissaa@tasmc.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>September 12, 2011</last_update_submitted>
  <last_update_submitted_qc>September 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michal Roll PhD,MBA</investigator_full_name>
    <investigator_title>Dr. Alissa Ash</investigator_title>
  </responsible_party>
  <keyword>TMS AD H2 coil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

